It’s time for a targeted option to change how generalized myasthenia gravis (gMG) is treated.
Start at the beginning: here are some important facts about gMG:
Now that we’ve covered the basics, let’s dive deeper and talk about how gMG works in the body.
In people who have gMG, the part of the immune system called the complement system doesn’t work correctly. Instead of helping the body fight off sickness by attacking intruders like bacteria and viruses, it attacks muscle cells right at the spot where the nerve meets the muscle, called the neuromuscular junction.
Damage at the neuromuscular junction makes it difficult for the muscles to get signals from the brain. The result is muscle weakness, the main symptom of gMG. That muscle weakness becomes worse as the muscle is used, and then may get better after the muscle is rested. The muscles affected can include those that control the:
When the respiratory system is affected, it can cause a life-threatening crisis and may require treatment in a hospital or intensive care unit.
There are treatments that can help.
- Right now, doctors can use cholinesterase inhibitors, corticosteroids, immunosuppressants, plasmapheresis, and/or intravenous immune globulin to manage the symptoms of gMG, though these therapies are not all specifically approved as treatments for gMG.
- If those treatments don’t work, doctors sometimes try adding a complement inhibitor. The goal of our ongoing research is to develop a convenient complement inhibitor designed to be used early in treatment, which we believe has the potential to provide benefit to more patients.
Our commitment to gMG does not end with research. At Ra Pharma, we are working to spread awareness of the disease by partnering in local fundraising walks and events and providing information about our work on the disease that can easily be shared.
For more details about MG and gMG or to become more involved in the community, visit the following:
To learn more about clinical trials, visit the following:
Ra Pharma is currently enrolling in a Phase 3 clinical trial, the RAISE study, to evaluate the efficacy and safety of zilucoplan for patients with gMG. To see if you could qualify for this study or to learn more, click here.